U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H27F4N3O3S
Molecular Weight 525.559
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ODANACATIB

SMILES

CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C2=CC=C(C=C2)S(C)(=O)=O)C(F)(F)F)C(=O)NC3(CC3)C#N

InChI

InChIKey=FWIVDMJALNEADT-SFTDATJTSA-N
InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H27F4N3O3S
Molecular Weight 525.559
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18226527 | https://www.ncbi.nlm.nih.gov/pubmed/27681784

Odanacatib is a potent, selective, and neutral cathepsin K inhibitor, an enzyme involved in bone resorption. Merck & Co was developing odanacatib, a once-weekly, oral Odanacatib, for the treatment of postmenopausal osteoporosis and osteoporosis in men. Merck & Co. has discontinued development of its cathepsin K inhibitor odanacatib, citing an increased risk of cardiovascular events for the osteoporosis drug.

Originator

Approval Year

Unknown
134361
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8228
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
663
Unknown

Approved Use

Unknown
Primary
Phase III
663
Unknown

Approved Use

Unknown
Primary
Phase III
663
Unknown

Approved Use

Unknown
Primary
Phase II
1144
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
839.2 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
154.7 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
477.3 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.76 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
2.23 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
-0.01 mg single, oral
dose: -0.01 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
353.5 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
56.2 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27402726
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ODANACATIB
ODANACATIB
 ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1.82 nM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.1 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
3.2 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.4 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.73 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
2.11 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
-0.01 mg single, oral
dose: -0.01 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
6.4 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.7 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27402726
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ODANACATIB
ODANACATIB
 ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1.87 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
62.6 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
59.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
48.2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
104.4 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27402726
1 mg single, intravenous
dose: 1 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered: ODANACATIB
ODANACATIB
 ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
50.5 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/23013236
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ODANACATIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: HIGH-FAT
Doses

Doses

DosePopulationAdverse events​
50 mg 1 times / week multiple, oral (unknown)
Studied dose
Dose: 50 mg, 1 times / week
Route: oral
Route: multiple
Dose: 50 mg, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/33200257
unhealthy, ADULT
n = 146
Health Status: unhealthy
Condition: osteoporosis
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 146
Sources:
https://pubmed.ncbi.nlm.nih.gov/33200257
Disc. AE: Myalgia...
AEs leading to
discontinuation/dose reduction:
Myalgia (0.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/33200257
300 mg 1 times / day multiple, oral (starting)
Highest recorded dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
healthy
n = 56
Health Status: healthy
Sex: M+F
Food Status: FASTED
Population Size: 56
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
Other AEs: Abdominal pain, Application-site erosion...
Other AEs:
Abdominal pain (5.4%)
Application-site erosion (5.4%)
Application-site erythema (17.9%)
Pruritus (7.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
50 mg 1 times / week multiple, oral (unknown)
Studied dose
Dose: 50 mg, 1 times / week
Route: oral
Route: multiple
Dose: 50 mg, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/26879200
unhealthy
n = 28
Health Status: unhealthy
Condition: low bone mineral density
Sex: F
Food Status: UNKNOWN
Population Size: 28
Sources:
https://pubmed.ncbi.nlm.nih.gov/26879200
Disc. AE: Basal cell carcinoma...
AEs leading to
discontinuation/dose reduction:
Basal cell carcinoma (3.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26879200
AEs

AEs

AESignificanceDosePopulation
Myalgia 0.7%
Disc. AE
50 mg 1 times / week multiple, oral (unknown)
Studied dose
Dose: 50 mg, 1 times / week
Route: oral
Route: multiple
Dose: 50 mg, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/33200257
unhealthy, ADULT
n = 146
Health Status: unhealthy
Condition: osteoporosis
Age Group: ADULT
Sex: M
Food Status: UNKNOWN
Population Size: 146
Sources:
https://pubmed.ncbi.nlm.nih.gov/33200257
Application-site erythema 17.9%
300 mg 1 times / day multiple, oral (starting)
Highest recorded dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
healthy
n = 56
Health Status: healthy
Sex: M+F
Food Status: FASTED
Population Size: 56
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
Abdominal pain 5.4%
300 mg 1 times / day multiple, oral (starting)
Highest recorded dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
healthy
n = 56
Health Status: healthy
Sex: M+F
Food Status: FASTED
Population Size: 56
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
Application-site erosion 5.4%
300 mg 1 times / day multiple, oral (starting)
Highest recorded dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
healthy
n = 56
Health Status: healthy
Sex: M+F
Food Status: FASTED
Population Size: 56
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
Pruritus 7.1%
300 mg 1 times / day multiple, oral (starting)
Highest recorded dose
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
healthy
n = 56
Health Status: healthy
Sex: M+F
Food Status: FASTED
Population Size: 56
Sources:
https://pubmed.ncbi.nlm.nih.gov/31175709
Basal cell carcinoma 3.6%
Disc. AE
50 mg 1 times / week multiple, oral (unknown)
Studied dose
Dose: 50 mg, 1 times / week
Route: oral
Route: multiple
Dose: 50 mg, 1 times / week
Sources:
https://pubmed.ncbi.nlm.nih.gov/26879200
unhealthy
n = 28
Health Status: unhealthy
Condition: low bone mineral density
Sex: F
Food Status: UNKNOWN
Population Size: 28
Sources:
https://pubmed.ncbi.nlm.nih.gov/26879200
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1709

inhibitor
1579
inhibitor
1752
inhibitor
1599

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1509

CYP2C19
1463
CYP2C8
688

P-gp
1527
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1673
 no
yes (co-administration study)
Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure.
CYP2C19
1537
 no
yes (co-administration study)
Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure.
CYP2C9
1803
 no
yes (co-administration study)
Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure.
CYP3A4
1909
 no
yes (co-administration study)
Comment: Coadministration did not affect R( )- and S(-)-warfarin exposure.
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1709
 major
CYP2C8
688
 minor
P-gp
1527
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1632
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY105556
https://www.001chemical.com/chem/search?q=DY105556
1PlusChem LLC
1P003A9R
https://www.1pchem.com/search?query=1P003A9R
A2B Chem
AB52479
http://a2bchem.com/prod/AB52479
AChemBlock
10356
http://www.achemblock.com/catalogsearch/result/?q=10356
AK Scientific
Y0388
https://aksci.com/item_detail.php?cat=Y0388
Aceschem
ACF023007
https://www.aceschem.com/catalog/search.do?q=ACF023007
Angene
AGN-PC-0SVOB7
http://www.angenechemical.com/productshow/AGN-PC-0SVOB7.html
ApexBio Technology
A2487
https://www.apexbt.com/catalogsearch/result/?q=A2487
AstaTech
83152
http://astatechinc.com/CPSResult.php?CRNO=83152
Axon MedChem
1771
https://www.axonmedchem.com/product/1771
BLD Pharm
BD242186
http://www.bldpharm.com/search/Search.html?keyword=BD242186
BOC Sciences
603139-19-1
http://www.bocsci.com/description.asp?cas=603139-19-1
Cayman Chemical
21466
http://www.caymanchem.com/app/template/Product.vm/catalog/21466
Chem Scene
CS-0277
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0277
ChemShuttle
104830
https://www.chemshuttle.com/catalogsearch/result/?q=104830
Combi-Blocks
QK-7612
http://www.combi-blocks.com/cgi-bin/find.cgi?QK-7612
KeyOrganics
AS-19562
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-19562
Lab Seeker
SC-69096
http://www.labseeker.com/search.php?keywords=SC-69096&category=0
LabSeeker
SC-69096
http://www.labseeker.com/search.php?keywords=SC-69096&category=0
Matrix Scientific
125269
http://www.matrixscientific.com/125269.html
MedChem Express
HY-10042
https://www.medchemexpress.com/search.html?q=HY-10042&ft=&fa=&fp=
MolPort
MolPort-021-804-981
https://www.molport.com/shop/molecule-link/MolPort-021-804-981
Molcore
MC105556
http://www.molcore.com/CatMC105556.html
Molnova
M15252
https://www.molnova.com/en/serch-list.html?keywords=M15252
MuseChem
I004270
https://www.musechem.com/product/I004270.html
ShangHai Biochempartner
BCP000132
http://www.biochempartner.com/search_BCP000132
Synovel
SN-0270
http://www.synovellab.com/?s=SN-0270&submit=Search
Synthonix
14866
https://synthonix.com/catalogsearch/result/?q=14866
TargetMol
T6035
https://www.targetmol.com/search?keyword=T6035
Tetrahedron
TS90038
http://www.thsci.com/search.do?q=TS90038
eMolecules
108759429
https://orderbb.emolecules.com/search/#?query=108759429
eMolecules
275178454
https://orderbb.emolecules.com/search/#?query=275178454
eMolecules
300651548
https://orderbb.emolecules.com/search/#?query=300651548
eMolecules
42777428
https://orderbb.emolecules.com/search/#?query=42777428
eNovation Chemicals
D596979
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D596979&searchbtn.x=0&searchbtn.y=0
mcule
MCULE-6871213580
https://mcule.com/MCULE-6871213580/
mcule
MCULE-8587680000
https://mcule.com/MCULE-8587680000/
PubMed

PubMed

TitleDatePubMed
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
2008 Feb 1
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
2013 Feb
Patents

Patents

07375134
3
07973037
2
08318748
1
08772336
1

Sample Use Guides

In Vivo Use Guide
Merck is conducting a long-term phase II trial that is assessing four different doses of odanacatib (3mg, 10mg, 25mg and 50mg once-weekly for 2 years) in women with postmenopausal osteoporosis (NCT00112437; EudraCT2005-001511-22). Results from this phase IIb study showed that odanacatib 50mg increased bone mineral density (BMD) from baseline, and was generally safe and well tolerated.
Route of Administration: Oral
In Vitro Use Guide
1 nM odanacatib had suppressive effects on the expression levels of inflammatory cytokines in murine RAW 264.7 cells were cultured in the presence of the receptor activator of NF-kB and lipopolysaccharide
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:34:04 UTC 2023
Edited
by admin
on Wed Jul 05 23:34:04 UTC 2023
Record UNII
N673F6W2VH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ODANACATIB
INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
MK0822
Code English
ODANACATIB [USAN]
Common Name English
ODANACATIB [MI]
Common Name English
ODANACATIB [MART.]
Common Name English
ODANACATIB [JAN]
Common Name English
MK-0822
Code English
odanacatib [INN]
Common Name English
Odanacatib [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C67439
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
NCI_THESAURUS C783
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
Code System Code Type Description
INN
8962
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
SMS_ID
100000128030
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
WIKIPEDIA
ODANACATIB
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
DRUG BANK
DB06670
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
CAS
603139-19-1
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
NCI_THESAURUS
C66981
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
USAN
TT-63
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
EPA CompTox
DTXSID40209075
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
FDA UNII
N673F6W2VH
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
ChEMBL
CHEMBL481611
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
MESH
C527128
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
MERCK INDEX
M8131
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY Merck Index
PUBCHEM
10152654
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
EVMPD
SUB34600
Created by admin on Wed Jul 05 23:34:04 UTC 2023 , Edited by admin on Wed Jul 05 23:34:04 UTC 2023
PRIMARY
Related Record Type Details
CATHEPSIN K
TARGET -> INHIBITOR
SELECTIVE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of ODANACATIB
EXCRETED UNCHANGED
URINE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Structure of ODANACATIB
EXCRETED UNCHANGED
FECAL
Related Record Type Details
Structure of .BETA.-D-GLUCOPYRANURONIC ACID, 1-ESTER WITH 4-FLUORO-N-((1S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)(1,1'-BIPHENYL)-4-YL)ETHYL)-L-LEUCINE
METABOLITE -> PARENT
URINE
Structure of (4S)-5-((1-CYANOCYCLOPROPYL)AMINO)-2-FLUORO-2-METHYL-5-OXO-4-(((1S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)(1,1'-BIPHENYL)-4-YL)ETHYL)AMINO)PENTYL .BETA.-D-GLUCOPYRANOSIDURONIC ACID
METABOLITE -> PARENT
URINE
Structure of 4-FLUORO-N-((1S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)(1,1'-BIPHENYL)-4-YL)ETHYL)-L-LEUCYL-2-(1-AMINOCYCLOPROPYL)-4,5-DIHYDRO-4-THIAZOLECARBONYLGLYCINE
METABOLITE -> PARENT
URINE
Structure of (2S)-N-(1-CYANOCYCLOPROPYL)-4-FLUORO-5-HYDROXY-4-METHYL-2-(((1S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)(1,1'-BIPHENYL)-4-YL)ETHYL)AMINO)PENTANAMIDE
METABOLITE -> PARENT
FECAL
Structure of (1S)-2,2,2-TRIFLUORO-1-(4'-(METHYLSULFONYL)(1,1'-BIPHENYL)-4-YL)ETHYL .BETA.-D-GLUCOPYRANOSIDURONIC ACID
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of ODANACATIB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966